Clinical Trial Update: A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of guadecitabine (SGI-110) with ipilimumab in unresectable or metastatic melanoma; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• SGI-110 (guadecitabine)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Italian Network for Tumor Biotherapy Foundation | Conditions: Metastatic Melanoma | Phase 1 | Status: UNKNOWN